NCT06205602View on ClinicalTrials.gov

Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa

PHASE2RecruitingINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

January 17, 2025

Primary Completion Date

February 16, 2029

Study Completion Date

February 16, 2029

Conditions
HIV-1-infection
Interventions
DRUG

3BNC117-LS

30 mg/kg to be administered via IV at Step 1 (Day 1)

DRUG

10-1074-LS

10 mg/kg to be administered intravenously at Step 1 (Day 1)

DRUG

Placebo for 3BNC117-LS

0.9% Sodium Chloride Injection to be administered intravenously at Step 1 (Day 1)

DRUG

Placebo for 10-1074-LS

0.9% Sodium Chloride Injection) to be administered IV at Step 1 (Day 1)

Trial Locations (4)

2193

RECRUITING

University of the Witwatersrand Helen Joseph (WITS HJH) CRS (11101), Johannesburg

4011

RECRUITING

CAPRISA eThekwini CRS (31422), Durban

Unknown

RECRUITING

Gaborone CRS (12701), Gaborone

4013 SF

RECRUITING

Durban Adult HIV CRS (11201), Durban

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK